Clinical study of combined application of recombinant human adenovirus p53 injected into thoracic cavity and abdominal cavity with cisplatin therapy in treating malignant thoracic cavity and abdomen cavity effusion
ZHAO Fengling,LUO Shewen,MAO Jifen,SONG Xiaoping,LIU Minghe,and XU Li
First Cadres Department, General Hospital of Chinese People’s Armed Police Forces, Beijing 100039, China
Abstract：Objective To evaluate the clinical value of combined application of recombinant human adenovirus p53 injected into thoracic cavity and abdominal cavity with cisplatin therapy in treating malignant thoracic cavity and abdomen cavity effusion. Methods Forty-two patients with malignant thoracic or abdomen cavity effusion in this hospital from Janurary 2010 to December 2012 were included in this study. The patients were divided into two groups: for observation group (n=21), recombinant 2?1012 VP human adenovirus p53 injected into thoracic cavity, recombinant 4?1012 VP human adenovirus p53 injected into abdominal cavity after outflow effusion by puncture. Patients were demanded to change their position after injection, 40 mg/m2 cisplatin injection was performed after 24 hours. The injection was repeated once every week and 4 times was a therapy period. For control group (n=21), only cisplatin was used. The clinical grading, quality of life, Kashi grading, and untoward reactions were observed and recorded for all patients. Survival period was recorded at the same time. Results The efficiency rate of therapy(CR+PR+SD)for observation group was 85.7%(18/21), while that for control group was 57.1%(12/21)(P<0.05). The increase in Kashi grading of living quality was 76.2%(16/21), while that for control group was 38.1%(8/21)(P<0.05). Conclusions Combined application of recombinant human adenovirus p53 injected into thoracic cavity and abdominal cavity with cisplatin therapy in treating malignant thoracic cavity and abdomen cavity effusion shows great clinical value with mild untoward reaction.
2014, Vol. 25 
